Associated Papers
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
Comprehensive genetic screening of the South African Parkinson's disease study collection using the NeuroBooster array.
Step K et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Large-scale genetic characterization of Parkinson's disease in the African and African admixed populations.
Akçimen F et al.
Brain : a Journal of Neurology, 2025
LRRK2 rare-variant per-domain genetic burden in Parkinson's Disease: association confined to the kinase domain.
Parlar SC et al.
Npj Parkinson's Disease, 2025
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson's disease comorbidity.
Kars ME et al.
Genome Medicine, 2024
Understanding monogenic Parkinson's disease at a global scale.
Junker J et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Genetic landscape of Parkinson's disease and related diseases in Luxembourg.
Landoulsi Z et al.
Frontiers in Aging Neuroscience, 2023
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG et al.
Parkinsonism & Related Disorders, 2021
The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation.
Bae EJ et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2020
Novel Variants in LRRK2 and GBA Identified in Latino Parkinson Disease Cohort Enriched for Caribbean Origin.
Nuytemans K et al.
Frontiers in Neurology, 2020
Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo.
Kozina E et al.
Brain : a Journal of Neurology, 2018
Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E et al.
Advances in Neurobiology, 2017
Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance.
Lubbe SJ et al.
Human Molecular Genetics, 2016
High-Resolution Melting Analysis as a Developed Method for Genotyping the PD Susceptibility Loci in LRRK2 Gene.
Jiang E et al.
Journal of Clinical Laboratory Analysis, 2015
Structural and functional in silico analysis of LRRK2 missense substitutions.
Cardona F et al.
Molecular Biology Reports, 2014
Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity.
Roth JA et al.
Neurotoxicology, 2013
Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe.
Rubio JP et al.
Human Mutation, 2012
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T et al.
Acs Chemical Neuroscience, 2012
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA et al.
The Lancet. Neurology, 2011
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ et al.
The Biochemical Journal, 2010
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Nuytemans K et al.
Human Mutation, 2010
Identification of four novel potentially Parkinson's disease associated LRRK2 variations among Iranian patients.
Shojaee S et al.
Neuroscience Letters, 2009
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U et al.
The Febs Journal, 2009
LRRK2 gene variation and its contribution to Parkinson disease.
Paisán-Ruiz C
Human Mutation, 2009
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
Biskup S et al.
Biochimica Et Biophysica Acta, 2009
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN et al.
Journal of Neuroscience Research, 2009
Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls.
Paisán-Ruíz C et al.
Human Mutation, 2008
Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI et al.
Neuro-signals, 2008
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B et al.
Human Molecular Genetics, 2007
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
Jaleel M et al.
The Biochemical Journal, 2007
A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases.
Mandemakers W et al.
Journal of Cell Science, 2007
LRRK2 and Parkinson's disease in Norway.
Toft M et al.
Acta Neurologica Scandinavica. Supplementum, 2007
LRRK2 expression in normal and pathologic human brain and in human cell lines.
Miklossy J et al.
Journal of Neuropathology and Experimental Neurology, 2006
LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF et al.
Trends in Neurosciences, 2006
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.
Khan NL et al.
Brain : a Journal of Neurology, 2005